Factores pronósticos clínicos, inmunohistoquímicos, clasificadores y eventos adversos determinantes en las metástasis a distancia en los carcinomas mamarios infiltrantes
Resumen
Palabras clave
Referencias
Lester SC. The breast. En: Kumar V, editor. Robbins and Cotran Pathology basis of disease [CD-ROM]. Philadelphia: Elsevier; 2010.
Hunter K. Host genetics influence tumour metastasis. Nat Rev Cancer [Internet]. 2006 Feb [citado 20 Oct 2014];6(2):141-146. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/16491073
García Fernández A, Chabrera C, García Font M, Fraile M, Gónzalez S, Barco I, et al. Differential survival and recurrence patterns of patients operated for breast cancer according to the new immunohistochemical classification: analytical survey from 1997 to 2012. Tumour Biol [Internet]. 2013 Aug [citado 20 Oct 2014];34(4):2349-55. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/23605321
Kim H, Cho J, Kwon SY, Kang SH. Biologic subtype is a more important prognostic factor than nodal involvement in patients with stages I and II breast carcinoma. Ann Surg Treat Res [Internet]. 2016 Jan [citado 20 May 2017];90(1):1-9. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/26793686
Ruiz Jorge L, Alegret Rodríguez M, Machado Puerto I, Llombart-Bosh A. Factores pronósticos morfológicos determinantes en las metástasis a distancia en los carcinomas mamarios infiltrantes. Acta Méd Centro [Internet]. 2018 [citado 28 Jun 2018];12(3):[aprox. 11 p.]. Disponible en: http://www.revactamedicacentro.sld.cu/index.php/amc/article/view/912/1188
Ellis IO, Schnitt SJ, Sastre-Garau X, Bussolati G, Tavassoli FA, EusebiV. Tumours of the breast. En: Tavassoli FA, Devilee P, editors. Pathology & Genetics. Tumours of the breast and female genital organs [Internet]. Lyon: OMS; 2003. p. 10-59. Disponible en: https://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb4/BB4.pdf
Takahashi H, Watanabe K, Takahashi M, Taguchi K, Sasaki F, Todo S. The impact of bilateral breast cancer on the prognosis of breast cancer: a comparative study with unilateral breast cancer. Breast Cancer [Internet]. 2005 [citado 20 Oct 2014];12(3):196-202. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/16110289
Tsyhyka DY, Hotko YS, Devinyak OT. Receptor status of tumor as prognostic factor in patients with bilateral breast cancer. Exp Oncol [Internet]. 2013 Dec [citado 20 Oct 2014];35(4):291-4. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/24382440
Guarneri V, Barbieri E, Piacentini F, Giovannelli S, Ficarra G, Frassoldati A, et al. Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis. Int J Biol Markers [Internet]. 2010 Apr-Jun [citado 20 Oct 2014];25(2):104-11. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/20544688
Leidy J, Khan A, Kandil D. Basal-like breast cancer: update on clinicopathologic, immunohistochemical, and molecular features. Arch Pathol Lab Med [Internet]. 2014 Jan [citado 22 Sept 2015];138(1):37-43. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/24377810
Takahashi S, Moriya T, Ishida T, Shibata H, Sasano H, Ohuchi N. Prediction of breast cancer prognosis by gene expression profile of TP53 status. Cancer Sci [Internet] 2008 Feb [citado 22 Sept 2015];99(2): 324-332. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/18271932
Hwang KT, Woo JW, Shin HC, Kim HS, Ahn SK, Moon HG, et al. Prognostic influence of BCL2 expression in breast cancer. Int J Cancer [Internet]. 2012 Oct [citado 20 Oct 2014];131(7):E1109-19. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22418857
Zaha DC, Lazăr E. Molecular characterization of apoptosis by the immunohistochemical evaluation of Bcl-2 in breast cancer. Rom J Morphol Embryol [Internet]. 2012 [citado 20 Oct 2014];53(1):155-60. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/22395515
Kumar V, Abbas AK, Aster JC. Neoplasia. En: Robbins basic pathology. 9th ed. Philadelphia: Elsevier; 2013. p. 280-283.
Engels CC, Ruberta F, de Kruijf EM, van Pelt GW, Smit VT, Liefers GJ, et al. The prognostic value of apoptotic and proliferative markers in breast cancer. Breast Cancer Res Treat [Internet]. 2013 Nov [citado 19 Dic 2014];142(2):323-39. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/24194179
Talley LI, Chhieng DC, Bell WC, Grizzle WE, Frost AR. Immunohistochemical detection of EGFR, p185erbB-2, Bcl-2 and p53 in breast carcinomas in pre-menopausal and post-menopausal women. Biotech Histochem [Internet]. 2008 Feb [citado 22 Sept 2015];83(1):5:14. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/18568671
Dawson S-J, Makretsov N, Blows FM, Driver KE, Provenzano E, Le Quesne J, et al. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer [Internet]. 2010 Aug [citado 20 Oct 2014];103(5):668-675. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938244/
Rakha E, Reis-Filho JS. Basal-like breast carcinoma: from expression profiling to routine practice. Arch Pathol Lab Med [Internet]. 2009 Jun [citado 3 Ago 2013];133(6):860-8. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/19492878
Morillo M, Cano R, Sánchez J, Jofré JJ, Vidal F, Cordón J. Aplicación del índice pronóstico de Nottingham en el carcinoma de mama operable. Rev Senol Patol Mamar [Internet]. 2002 [citado 10 Sep 2014];15:11-6. Disponible en: http://www.elsevier.es/es-revista-revista-senologia-patologia-mamaria-131-articulo-aplicacion-del-indice-pronostico-nottingham-13026838
Jensen A, Jacobsen JB, Nørgaard M, Yong M, Fryzek JP, Sørensen HT. Incidence of bone metastases and skeletal-related events in breast cancer patients: A population-based cohort study in Denmark. BMC Cancer [Internet]. 2011 [citado 3 Abr 2013];11:29. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/21261987
Fernández A, Hernández A, Martínez L, Urbistazu J, Saldivia F, Prince J. Metástasis óseas en adenocarcinoma de mama. Rev Venez Oncol [Internet]. 2008 [citado 3 Abr 2013];20(4):181-185. Disponible en: http://www.redalyc.org/articulo.oa?id=375640202003
Elnashar AT1, Ali el-SM, Gaber A. The prognostic value of triple negative in stage II/III breast cancer. J Oncol Pharm Pract [Internet]. 2012 Mar [citado 20 Abr 2013];18(1):68-75. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/21422149
Komoike Y, Akiyama F, Iino Y, Ikeda T, Akashi-Tanaka S, Ohsumi S, et al. Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases. Cancer [Internet]. 2006 Jan [citado 20 Abr 2013];106(1):35-41. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/16333848
Enlaces refback
- No hay ningún enlace refback.
Copyright (c) 2018 Lissette Ruiz Jorge, Milagros Alegret Rodríguez, Isidro Machado Puerto, Antonio Llombart-Bosh